About Cynapsus Therapeutics
Cynapsus Therapeutics is a Healthcare company based in Toronto (Canada) founded in 2004, and was acquired by Sunovion in August 2016. Treatments for CNS disorders, including Parkinsons OFF episodes, are developed. Cynapsus Therapeutics has raised $25.06 million across 6 funding rounds from investors including Orbimed, Sunovion and Aisling Capital. Cynapsus Therapeutics offers products and services including APL-130277. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is Cynapsus Therapeutics Inc.
Company details
Cynapsus Therapeutics was founded in 2004 in Toronto, Canada, within the biotechnology sector. Focus is placed on developing a sublingual thin film formulation of apomorphine hydrochloride, known as APL-130277, for managing OFF episodes in advanced Parkinsons disease patients. A Phase 2 clinical trial for this product candidate has been successfully completed. Operations center on CNS disorder treatments, with apomorphine currently approved only as a subcutaneous injection in the United States.
- Headquarters Toronto, Canada
- Stage Acquired
- SectorsHealthcare
- Website cynapsus.ca
- Social LinkedIn
- Acquired by Sunovion (Aug 2016)
- Legal Name Cynapsus Therapeutics Inc.
Products & Services of Cynapsus Therapeutics
Cynapsus Therapeutics offers a comprehensive portfolio of products and services, including APL-130277.
Sublingual thin film for on-demand management of Parkinson's OFF episodes.
Funding Insights of Cynapsus Therapeutics
Cynapsus Therapeutics has successfully raised a total of $25.06M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $16.75 million completed in April 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25.06M
- Total Rounds 6
- Last Round Post-IPO — $16.75M
- First Round $939,505
(Sep 2011)
- Investors Count 3
All 6 funding rounds of Cynapsus Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2015 | $16.75M | Post-IPO | – | – | |
| Jul 2014 | $500,000 | Grant | – | – | – |
| Apr 2014 | $20M | Series B | – | – | – |
| Mar 2013 | $4.12M | Series A | – | – | – |
| Sep 2011 | $939,505 | Seed | – | – | – |
| Sep 2011 | Debt – Conventional | – | – | – |
4 investors in total: 4 institutional.
Investors in Cynapsus Therapeutics
Cynapsus Therapeutics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Sunovion and Aisling Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Pharmaceutical company that specializes in treatment of CNS and respiratory ailments | 1984 | sunovion.com | Marlborough, United States |
Investor details for Cynapsus Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cynapsus Therapeutics
5 dated milestones of Cynapsus Therapeutics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Cynapsus Therapeutics is founded.
- Funding First funding round of $940K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $16.8M.
- Exit Acquired by Sunovion.
Web traffic of Cynapsus Therapeutics
The website of Cynapsus Therapeutics (cynapsus.ca) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 65.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cynapsus Therapeutics
Cynapsus Therapeutics was founded in 2004 and raised its 1st funding round 7 years after it was founded.
Cynapsus Therapeutics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Cynapsus Therapeutics is a funded company, having raised a total of $25.06M across 6 funding rounds to date. The company's 1st funding round was a Seed of $939.51K, raised on Sep 2011.
Cynapsus Therapeutics was founded in 2004 in Toronto, Canada, within the biotechnology sector. Focus is placed on developing a sublingual thin film formulation of apomorphine hydrochloride, known as APL-130277, for managing OFF episodes in advanced Parkinsons disease patients. A Phase 2 clinical trial for this product candidate has been successfully completed. Operations center on CNS disorder treatments, with apomorphine currently approved only as a subcutaneous injection in the United States.
Cynapsus Therapeutics offers APL-130277.
Cynapsus Therapeutics has 4 investors. Key investors include Orbimed, Sunovion, Aisling Capital, and Venrock.
Cynapsus Therapeutics operates through Cynapsus Therapeutics Inc..
Yes. Cynapsus Therapeutics was acquired by Sunovion in August 2016.